Bulk Orders 20+ bottles
Volume pricing applies automatically from three bottles and reaches 20% at twenty. Larger runs, institutional supply and custom timelines get a quote.
Ask about bulk
Neurocognitive Research
TAK-653 is a tablet product made for lab research. Each tablet holds 2MG. Each bottle holds 60 tablets, for 120MG of TAK-653 in total.
Bundle & save
Referral program · researchers save 10%, you earn 15% backThe compounds researchers order most, by verified order volume.
More ways to save
Volume pricing applies automatically from three bottles and reaches 20% at twenty. Larger runs, institutional supply and custom timelines get a quote.
Ask about bulkShipping batch TK01
Open the certificate matched to this shipping batch.
Verified test results
Each batch is analyzed by Freedom Diagnostics, an independent third-party laboratory, before release. Below is the report for lot TK01, summarized from the certificate the lab published.
This lot ships under its own published certificate. Open any certificate below, exactly as the lab released it.
Side by side
Peer-reviewed literature
Every reference below is a published, peer-reviewed record, linked to its PubMed entry. Provided for educational reference only - not product claims.
Important research notice
Not for human, veterinary, or food use. This product is sold exclusively for laboratory research purposes. It is not intended to diagnose, treat, cure, or prevent any disease, and has not been evaluated by the FDA.
All referenced publications and registries are sourced from peer-reviewed journals and official registries. They are provided for educational reference only and are not product claims.
By purchasing, you confirm you are a qualified researcher and will handle this product in accordance with all applicable laws and regulations.
Ready when you are
The lot on this page links to the signed certificate for that batch.
Research tablets
TAK-653 is a tablet product made for lab research. Each tablet holds 2MG. Each bottle holds 60 tablets, for 120MG of TAK-653 in total.
TAK-653 is also written TAK653. Its INN, the official generic name, is osavampator. It is a synthetic small molecule studied as a positive allosteric modulator of AMPA-type glutamate receptors.
Labs use it in controlled studies of AMPA receptor pathways and glutamate signaling. Work also covers synaptic plasticity, neurochemical signaling and cognitive pathways. Other models look at excitatory neurotransmission and how the central nervous system (CNS) responds.
We sell it as finished tablets with clear strength labels and a clean look. They suit labs that need set manufacturing standards. We run internal QA before release, and our own team packs and ships every order.
| Compound | TAK-653 (TAK653, osavampator) |
|---|---|
| Strength | 2MG per tablet |
| Count | 60 tablets per bottle |
| Total content | 120MG per bottle |
| Format | finished tablet research product |
| Formula and weight on this page | C₁₉H₂₃N₃O₃S, 373.5 g/mol |
It is studied in models of AMPA receptor activity and receptor modulation. Models also cover excitatory neurotransmission and how glutamate pathways respond. In a 2021 study, TAK-653 bound the AMPA receptor in a glutamate-dependent way. In rat neurons, it showed minimal agonist activity on its own (Suzuki et al., 2021).
It is also used in lab studies of synaptic signaling and plasticity. Studies also cover CNS adaptation and cognitive pathways.
Research on TAK-653 looks at how AMPA receptor signaling may affect synaptic communication and neural network activity. It also covers cognitive pathway models and glutamate response systems. These studies use controlled lab conditions.
The 2MG tablets are clearly labeled and supplied as finished tablets. With 120MG per bottle, labs get a set amount for structured handling and records.
Keep the tablets sealed in the original container at room temperature (15 to 25°C), away from moisture and direct light. The buy box shows the lot now shipping under "Your purchasing batch." The "View COA" button opens that lot's certificate. Every lot is also listed in the COA portal. For identity data and what published studies examined, read the TAK-653 research guide.
Primary research relevant to the named compound or clearly identified component is linked below. Experimental results depend on identity, model and formulation.
Characterized glutamate-dependent receptor potentiation. Positive allosteric modulation should not be described as equivalent to direct receptor agonism.
Retain the product label and lot number with the research record. Review the matching certificate of analysis for test coverage and reported results. Identity, analytical purity, measured content, sterility and endotoxin testing are distinct assessments; one does not establish the others.
Follow the supplied label and your laboratory’s validated handling and storage procedures. Record the vehicle, concentration and preparation date where relevant. Dry-material stability does not establish the shelf life of a prepared solution.
It is the stated quantity per unit, separate from the number of units in the bottle. A purity percentage is not a measurement of milligrams per capsule or tablet. Use the matching lot report for the measurements actually performed.
Open the linked certificate for the assigned lot or use the COA portal. Check sample identity, methods, date and reported measurements. A report for another lot or formulation is not a substitute.
The references describe the materials and conditions used by their authors. They do not establish that this commercial formulation was tested. For blends, evidence on an individual component does not validate the finished mixture or establish synergy.
Yes. Osavampator is TAK-653's international nonproprietary name, and NBI-1065845 is the code under which Neurocrine Biosciences studied it; PubChem lists all three names under one record, C₁₉H₂₃N₃O₃S at 373.5 g/mol, the formula and weight on this page. Takeda scientists discovered it as an AMPA receptor potentiator with low agonist activity.
As a positive allosteric modulator, or potentiator, of AMPA-type glutamate receptors with minimal agonist activity. In Takeda's 2021 characterization it bound the ligand-binding domain of recombinant AMPA receptors in a glutamate-dependent manner, strictly potentiated glutamate-induced calcium influx in CHO cells expressing human GluA1, and in primary neurons augmented AMPA-induced responses with little agonistic effect.
Yes, as research history. A randomized, double-blind, placebo-controlled crossover study in 24 healthy volunteers measured motor-evoked potentials and NeuroCart tests after single amounts, and phase 3 trials begun in 2025 include randomized, double-blind, placebo-controlled add-on studies of NBI-1065845 in adults with major depressive disorder that measure change in Montgomery-Asberg Depression Rating Scale (MADRS) score.
Disguised Alpha lists TAK-653 here for laboratory research only, as tablets: 2MG per tablet in bottles of 60 tablets per bottle, with 120MG total TAK-653 content. Its lot's certificate of analysis, from Freedom Diagnostics, is shown on this page, and it ships from the US West Coast, by FedEx 2-Day shipping.
The current certificate is matched to the selected product option and assigned shipping batch.
Enable JavaScript to view the certificate for your selected option.
We share visit and purchase data with advertising partners to measure and show ads. Some US state laws, including California's, call that a sale or sharing of personal information. You can turn it off for this browser.
Ad sharing is on in this browser.
Saved in this browser only. For your account or other devices, email support@disguisedalpha.com. Privacy Policy